Literature DB >> 9129011

Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.

M Furlan1, R Robles, M Solenthaler, M Wassmer, P Sandoz, B Lämmle.   

Abstract

In patients with thrombotic thrombocytopenic purpura (TTP), excessive intravascular platelet aggregation has been associated with appearance in plasma of unusually large von Willebrand factor (vWF) multimers. These extremely adhesive vWF multimers may arise due to deficiency of a "depolymerase" cleaving vWF to smaller molecular forms, either by reducing the interdimeric disulfide bridges or by proteolytic degradation. We studied the activity of a recently described vWF-cleaving protease in four patients with chronic relapsing TTP. Diluted plasma samples of TTP patients were incubated with purified normal human vWF in the presence of a serine protease inhibitor, at low ionic strength, and in the presence of urea and barium ions. The extent of vWF degradation was assayed by electrophoresis in sodium dodecyl sulfate-agarose gels and immunoblotting. Four patients, that included two brothers, with chronic relapsing TTP displayed either substantially reduced levels or a complete absence of vWF-cleaving protease activity. In none of these patient plasmas was an inhibitor of or an antibody against the vWF-cleaving protease established. Our data suggest that the unusually large vWF multimers found in TTP patients may be caused by deficient vWF-cleaving protease activity. Deficiency of this protease may be inherited in an autosomal recessive manner and seems to predispose to chronic relapsing TTP. The assay of the vWF-cleaving protease activity may be used as a sensitive diagnostic tool for identification of subjects with a latent TTP tendency.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129011

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  88 in total

Review 1.  Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  S L Allford; S J Machin
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

2.  A new name in thrombosis, ADAMTS13.

Authors:  J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

3.  Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  Flora Peyvandi; Roberta Palla; Luca A Lotta
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

4.  von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins.

Authors:  Anil K Chauhan; Janka Kisucka; Colin B Lamb; Wolfgang Bergmeier; Denisa D Wagner
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

Review 5.  Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura.

Authors:  Satoru Kosugi; Masanori Matsumoto; Yasushi Ohtani; Hironori Take; Hiromichi Ishizashi; Yoshihiro Fujimura; Jun Kuyama
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

6.  Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.

Authors:  Masami Niiya; Masayuki Endo; Dezhi Shang; Philip W Zoltick; Nidal E Muvarak; Wenjing Cao; Sheng-Yu Jin; Christopher G Skipwith; David G Motto; Alan W Flake; X Long Zheng
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

7.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

8.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 9.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

10.  Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.

Authors:  Kenji Nishio; Patricia J Anderson; X Long Zheng; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.